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Transcription of the prostate-specific antigen (PSA)
gene is androgen regulated. The PSA promoter contains
at position 2170 the sequence AGAACAgcaAGTGCT,
which is closely related to the ARE (androgen response
element) consensus sequence GGTACAnnnTGTTCT.
This sequence is a high affinity androgen receptor (AR)
binding site and acts as a functional ARE in transfected
LNCaP cells. A 35-base pair segment starting at 2400
(ARR: androgen response region; GTGGTGCAGGGAT-
CAGGGAGTCTCACAATCTCCTG) cooperates with the
ARE in androgen induction of the PSA promoter. A con-
struct with three ARR copies linked to a minimal PSA
promoter showed a strong (104-fold) androgen induced
activity. The ARR was also able to confer androgen re-
sponsiveness to a minimal thymidine kinase promoter.
Both AR binding and transcriptional activity resided in
a 20-base pair ARR subfragment: CAGGGATCAGG-
GAGTCTCAC (2S). Mutational analysis indicated that
the sequence GGATCAgggAGTCTC in the 2S fragment is
a functionally active, low affinity AR binding site. Like
AR, the glucocorticoid receptor was able to stimulate
PSA promoter activity. Both the ARE and ARR are in-
volved in dexamethasone regulation of the PSA pro-
moter. Both the AR and glucocorticoid receptor were
20–100-fold more active on ARR-PSA and ARR-thymi-
dine kinase promoter constructs in LNCaP cells than in
other cell types (COS, HeLa, Hep3B, and T47D cells),
indicating (prostate) cell specificity.
Androgens exert their function via the intracellular andro-
gen receptor (AR),1 which is a member of the family of the
steroid hormone receptors (see for reviews, Refs. 1 and 2). Upon
ligand binding, steroid receptors interact with specific DNA
sequences and regulate the transcriptional activity of target
genes (1–3). The DNA structures to which steroid receptors
bind with high affinity are imperfect palindromic sequences,
separated by a 3-base pair spacer. The consensus sequence of
the response element for the glucocorticoid receptor (GR), pro-
gesterone receptor, and AR is identical: GGTACAnnnTGTTCT
(hormone response element) (1–6). However, in natural target
genes, the binding site can deviate considerably from the con-
sensus sequence. Analysis of natural and synthetic promoters
has shown that steroid receptors are able to act synergistically
with a variety of other transcription factors (2, 7–9). Synergis-
tical interaction of two hormone response elements has also
been observed (7, 8). At present it is unclear how specificity of
the AR/GR/progesterone receptor response operates. Several
mutually not exclusive mechanisms have been proposed, in-
cluding subtle differences in sequences flanking the hormone
response element, differences in affinity to general or specific
transcription factors, interaction with specific accessory pro-
teins, or differences in cellular concentration of the specific
receptors and ligands.
We use the prostate-specific antigen (PSA) gene as a model
for androgen regulated gene expression. PSA is expressed at
high level in the luminal epithelial cells of the prostate, and is
absent or expressed at very low levels in other tissues. PSA is
a member of the human kallikrein gene family, and is well
known as a prostate-specific tumor marker (10, 11). Further
members of the kallikrein gene family are the hGK-1 gene and
the tissue kallikrein gene (KLK-1) (12–15). The three genes are
clustered in an area of 60 kilobases on chromosome 19q13.2–
13.4 (15–18). In previous studies we and others have shown
that PSA mRNA expression is androgen-regulated (19–22).
Androgen-stimulated expression of PSA is at least partially
regulated at the level of transcription (22, 23). A functional
ARE (androgen responsive element) was defined at 2170 which
closely resembles the ARE consensus sequence (23).
In the present study we address the following questions: (i)
which PSA promoter elements, additionally to the ARE (2170)
are the major contributors to its androgen regulation, (ii) is
PSA promoter regulation AR specific, and (iii) is steroid hor-
mone regulation of the PSA promoter cell type specific.
MATERIALS AND METHODS
Cell Culture—LNCaP cells were cultured in RPMI 1640, supple-
mented with 5% fetal calf serum (Boehringer, Mannheim, Germany)
and antibiotics. For transfection, cells were grown in Dulbecco’s modi-
fied Eagle’s medium supplemented with 5% steroid-depleted (dextran-
charcoal treated) fetal calf serum. For examination of androgen-driven
promoter activation by transfection, the synthetic androgen R1881 (Du-
Pont NEN) was added to a final concentration of 1 nM. For examination
of glucocorticoid-regulated activation, a final concentration of 10 nM of
the synthetic glucocorticoid dexamethasone (Sigma) was used.
Construction of Plasmids—All plasmid constructs were prepared
using standard methods (24). The human AR expression plasmid pAR0,
the rat GR expression plasmid PSTC GR 3–795, and the plasmid
pRIT2TAR to produce AR(DBD) were described previously (25–27). The
promoter-less basic plasmid pLUC, which was used for cloning of PSA
promoter fragments in front of the LUC reporter gene, was derived from
pSLA3 (28) by insertion of an oligonucleotide containing a multiple
cloning site (HindIII, PvuII, NheI, BglII, and NcoI) in the HindIII and
NcoI sites of PSLA3. PSA-LUC constructs, PSA-4-LUC (EcoRI/HindIII;
2632/112), PSA-5-LUC (BglII/HindIII, 2539/112), PSA-6-LUC (XhoII/
HindIII; 2324/112), and PSA-7-LUC (NheI/HindIII; 2157/112) were
generated by ligation of the appropriate fragments in the multiple
* This work was supported by a grant from the Dutch Cancer Society.
The costs of publication of this article were defrayed in part by the
payment of page charges. This article must therefore be hereby marked
“advertisement” in accordance with 18 U.S.C. Section 1734 solely to
indicate this fact.
The nucleotide sequence(s) reported in this paper has been submitted
to the GenBankTM/EMBL Data Bank with accession number(s) X92553.
§ To whom correspondence should be addressed: Dept. of Pathology,
Erasmus University, P. O. Box 1738, 3000 DR Rotterdam, The Neth-
erlands. Tel.: 31-10-40-88227; Fax: 31-10-43-66660.
1 The abbreviations used are: AR, androgen receptor; GR, glucocorti-
coid receptor; PSA, prostate-specific antigen; ARE, androgen response
element; ARR, androgen response region; TK, thymidine kinase;
AR(DBD), AR DNA-binding domain.
THE JOURNAL OF BIOLOGICAL CHEMISTRY Vol. 271, No. 11, Issue of March 15, pp. 6379–6388, 1996
© 1996 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in U.S.A.
6379
 at Erasm
us M
C M
edical Library on January 2, 2007 
w
w
w
.jbc.org
D
ow
nloaded from
 
cloning site of pLUC.
Constructs PSA-8 to PSA-11-LUC were obtained by exonuclease III
digestion of PSA-2-CAT (2632/112)(23) from the SalI site. After exo-
nuclease III incubation according to the “Erase a base” protocol (Pro-
mega, Madison, WI), the plasmid was digested with HindIII and the
derived promoter fragments were ligated in the multiple cloning site of
pLUC. This resulted in the constructs PSA-8-LUC, starting at 2488,
PSA-9-LUC, starting at 2456, PSA-10-LUC starting at 2395 and PSA-
11-LUC, starting at 2376. Construct PSA-12-LUC was prepared by
introduction of a PstI site at position 2174 by polymerase chain reac-
tion. The polymerase chain reaction product was digested with PstI and
HindIII (112) and isolated from a 1.5% agarose gel. The isolated frag-
ment was ligated in the PstI and HindIII sites of the pLUC multiple
cloning site. One and three copies of the 2400 to 2366 oligomer were
cloned in front of the PSA-12-LUC and the TK-LUC construct. Double-
stranded oligonucleotides spanning ARR (2400 to 2366) 59-GATCCGT-
GGTGCAGGGATCAGGGAGTCTCACAATCTCCTG-39 were inserted
in the BamHI site of PSA-12-LUC and TK-LUC. Double stranded
oligonucleotides spanning three copies of the ARR-1S, GTGGTGCAGG-
GATCAGGGAG; ARR-2S, CAGGGATCAGGGAGTCTCAC; ARR-3S re-
gion, GAGTCTACAATCTCCTG and the ARR-2S mutants (mutations
are underlined); ARR-2S-1, CAGGGGATGAGGGAGTCTCAC; ARR-
2S-2, CAGGGATCAGGGACTCTCAC; and ARR-2S-3, CAGGGAT-
CAGCGAGTCTCAC, containing SalI compatible ends were inserted
in the SalI site of PSA-12-LUC. All constructs were verified by
sequencing.
Transfections—LNCaP cells were transfected according to the calcium
phosphate precipitation method essentially as described (29), using 1 3
106 cells per 25-cm2 flask, 5 mg of the appropriate PSA-LUC construct,
and where indicated 2.5 mg of pAR0 or PSTC GR 3–795 (GR expression
vector). After overnight incubation with the precipitate, the culture me-
dium was removed and replaced by phosphate-buffered saline, containing
15% glycerol (incubation for 90 s at room temperature). Subsequently,
transfected cells were incubated in culture medium in the absence or
presence of the appropriate hormone (R1881 or dexamethasone) for at
least 24 h. Transfections were performed at least three times in duplicate,
using at least two independent plasmid isolates.
Luciferase activities were corrected for variations in protein concen-
trations within the 100 ml of cell extracts. Luciferase activities and
relative induction factors are expressed as mean and standard error
(S.E.).
Luciferase Assay—Cells were washed once with phosphate-buffered
saline and lysed in 300 ml of lysis buffer (25 mM Tris phosphate, pH 7.8,
8 mM MgCl2, 1 mM dithiothreitol, 1% Triton X-100, 15% glycerol). Next,
100 ml of Luciferin (0.25 mM) (Sigma), 0.25 mM ATP was added to 100 ml
of each extract, and luciferase activity was measured in a LUMAC 2500
M Biocounter (LUMAC, Landgraaf, The Netherlands). After a delay of
2 s (according to supplier), the light emission during 5 s was recorded.
Gel Retardation Analysis—Nuclear extracts were prepared as de-
scribed by Dignam et al. (30). Coupled transcription/translation of hu-
man AR cDNA cloned in BluescriptII- KS (31) was carried out according
to the protocol of the manufacturer (Promega). AR synthesis was in the
presence of 10 mM ZnCl2. Production in Escherichia coli, and purifica-
tion of AR(DBD) was done as described previously (27).
Double stranded oligonucleotide probes used in gel retardations are
as follows.
ARE: 59 GATCCTTGCAGAACAGCAAGTGCTAGCTG 39
GAACGTCTTGTCGTTCACGATCGACCTAG
ARR: 59 GATCCGTGGTGCAGGGATCAGGGAGTCTCACAATCTCCTG 39
GCACCACGTCCCTAGTCCCTCAGAGTGTTAGAGGACCTAG
ARR-1S: 59 GATCCGTGGTGCAGGGATCAGGGAG 39
GCACCACGTCCCTAGTCCCTCCTAG
ARR-2S: 59 GATCCAGGGATCAGGGAGTCTCACG 39
GTCCCTAGTCCCTCAGAGTGCCTAG
ARR-3S: 59 GATCCGAGTCTCACAATCTCCTGAG 39
GCTCAGAGTGTTAGAGGACTCCTAG
ARR-2S-1: 59 GATCCAGGGATGAGGGAGTCTCACG 39
GTCCCTACTCCCTCAGAGTGCCTAG
ARR-2S-2: 59 GATCCAGGGATCAGGGACTCTCACG 39
GTCCCTAGTCCCTGAGAGTGCCTAG
ARR-2S-3: 59 GATCCAGGGATCAGCGAGTCTCACG 39
GTCCCTAGTCGCTCAGAGTGCCTAG
ARR-2S-4: 59 GATCCAGGGATCAGGGAGTTCCACG 39
GTCCCTAGTCCCTCAAGGTGCCTAG
ARR-2S-5: 59 GATCCAGGGAACAGGGTGTTCCACG 39
GTCCCTTGTCCCACAAGGTGCCTAG
Oligonucleotides 1–10
Probes were filled in with Moloney murine leukemia virus-reverse
transcriptase in the presence of [a-32P]dATP, and subsequently isolated
from nondenaturing polyacrylamide gel. For gel retardation assays,
20–50 3 103 cpm of each probe was added to 20 ml of reaction mixture,
containing 2 mg of poly(dI-dC), 2 mg of bovine serum albumin, 10 mM
ZnCl2, 1 mM dithiothreitol, and 2 ml of 10 3 binding buffer (100 mM
Hepes, pH 7.6, 300 mM KCl, 62.5 mM MgCl2, and 30% glycerol), and in
indicated cases 10 mg of LNCaP nuclear protein, in vitro translated AR
(7–10 fmol) or AR(DBD) (5 pmol). In experiments using the AR antibody
Sp197 (epitope amino acid residues 1–20), 0.1-ml portions of antiserum
were added to the reaction mixture (32). Incubation was for 30 min at
room temperature. In addition to oligonucleotides described above (100-
fold excess of) double-stranded oligonucleotides containing a C/EBP
binding site, 59-GACCTTACCACTTTCACAATCTGCTAG-39 (33), and a
glucocorticoid response element, 59-TCGACTGTACAGGATGTTCTAG-
CTACT-39 (Promega), were used in competition experiments. Samples
were loaded on a 4% polyacrylamide (19:1) gel and electrophoresed in a
50 mM Tris-HCl, 41.5 mM boric acid, 0.5 mM EDTA buffer for 2 h at 150
V and room temperature. Subsequently, gels were fixed, dried, and
exposed to x-ray film.
RESULTS
Deletion Mapping of the PSA Promoter: Effect of Androgen
Receptor Overexpression—In a previous study we analyzed an-
drogen regulation of the PSA promoter in COS cells which were
co-transfected with several different PSA promoter-chloram-
phenicol acetyltransferase reporter gene constructs and the AR
expression vector pAR0 (23). This resulted in the functional
characterization of an ARE (AGAACAgcaAGTGCT), which is
closely related to the consensus sequence, at position 2170,
and the identification of a second region, from 2539 to 2324,
important for PSA promoter activity.
Essentially the same data were obtained in LNCaP cells
which endogenously express the AR and PSA gene (Fig. 1A).
Transfection of PSA-4-LUC (2632/112) or PSA-5-LUC (2539/
112) resulted in an approximately 7-fold higher LUC activity
in the presence of R1881 than in its absence. Similar results
were found with constructs containing longer promoter frag-
ments (up to approximately 4 kilobases (data not shown)).
Removal of the 2539 to 2324 fragment (PSA-6-LUC) caused a
3.5-fold drop in relative induction. Subsequent removal of the
2324 to 2157 region (containing the ARE sequence at position
2170) resulted in the complete abolishment of androgen induc-
tion (construct PSA-7-LUC).
To investigate in more detail sequences in the 2539 to 2324
region important for PSA promoter activity, a series of exonu-
clease III deletions was generated (see Fig. 1B for PSA pro-
moter fragments in different constructs). Transfection of
LNCaP cells with constructs PSA-8-LUC, PSA-9-LUC, and
PSA-10-LUC resulted in a high (6–7-fold) androgen-regulated
PSA promoter activity, which is comparable to that of the
PSA-5 construct. Importantly, construct PSA-11-LUC, starting
at 2376, showed a low (2.2-fold), androgen-induced activity,
which is identical to that of PSA-6 (starting at 2324). These
results indicated sequences in the region 2395 to 2376 to be
essential for high androgen-induced PSA promoter activity.
Co-transfection with the AR expression plasmid pAR0 re-
sulted in considerably higher PSA promoter activity, both in
absolute values as well as in relative induction levels without
affecting the significance of the 2324 to 2157 region contain-
ing the ARE at position 2170, and the 2395 to 2376 region
(Fig. 1A). The co-transfection experiments showed again that
truncation of the promoter from 2395 to 2376 gives rise to a
markedly lower androgen induced activity (compare PSA-10
and PSA-11); deletion of the 2324 to 2157 region again re-
sulted in a complete loss of androgen inducibility of the PSA
promoter (compare PSA-6 and PSA-7).
Mutations in the ARE at 2170 in construct PSA-4-LUC
resulted in an almost complete inhibition of androgen activa-
tion of the PSA promoter (Ref. 23, and data not shown), indi-
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cating cooperativity between the 2395 to 2376 region and the
ARE sequence at position 2170.
Androgen Receptor Binding to the ARE(2170) Motif—To con-
firm that the sequence AGAACAgcaAGTGCT (2170) was able
to interact directly with the AR, gel retardation experiments
were done with LNCaP nuclear extracts, in vitro synthesized
AR, and AR DNA-binding domain (AR(DBD)) produced in E.
coli (Fig. 2, A-C). Using LNCaP nuclear extract, addition of an
AR-specific antibody (Sp197) to the incubation mixture re-
sulted in the visualization of a stable, specifically supershifted
AR-ARE(2170) complex (compare Fig. 2A, lanes 1–4). The re-
tarded complexes visible in the absence of antibody Sp197 (lane
1) are considered to be nonspecific because a 100-fold molar
excess of unlabeled ARE(2170) did not inhibit the formation of
these complexes (lane 3). Additionally, none of these bands was
supershifted after adding the specific AR antibody (lane 2).
A specific ARzARE(2170) retarded complex could be ob-
served if in vitro synthesized AR was used, addition of the
Sp197 antibody again resulted in the formation of a much more
stable supershifted complex (Fig. 2B). Application of the
AR(DBD) in the gel retardation assay revealed a clear
AR(DBD)zARE(2170) complex in the absence of antibody
(Fig. 2C).
Effect of the 2400 to 2366 Fragment (ARR) on Basal PSA
FIG. 1. Androgen regulation of the PSA promoter in LNCaP cells. A, LNCaP cells were transfected with PSA-LUC constructs (left panel)
and with PSA-LUC constructs plus the AR expression plasmid pAR0 (right panel) as described under “Materials and Methods.” Start positions of
PSA promoter constructs are indicated below the figure and in B. After overnight incubation with the precipitate, transfected cells were further
incubated in the presence or absence of 1 nM R1881 for 24 h. The absolute activity and relative induction factor were calculated as the mean of five
or more independent transfection experiments, which were all done in duplicate. Closed bar, activity in the presence of R1881; open bar, activity
in the absence of R1881. Hormone induction is given at the top of the bars. S.E. of absolute activity is represented by a vertical stripe; S.E. of
induction is given in parentheses. The TATA box is represented by a hatched box; the ARE by a black box. B, sequence of the proximal PSA
promoter. Transcription start sites are indicated by asterisks. Arrows indicate starting points of constructs used in transfections. The ARE
sequence starting at position 2170 is double underlined, the ARR(2400) is single underlined, and the TATA box is indicated by stripes.
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and TK Promoter Activity—To further elucidate the properties
of the 2395 to 2375 region, one and three copies of an oligo-
nucleotide, spanning this region (2400 to 2366; GTGGTG-
CAGGGATCAGGGAGTCTCACAATCTCCTG (denoted ARR,
androgen response region) underlined in Fig. 1B) were inserted
in front of a “minimal” PSA promoter, starting at position
2174. The minimal PSA promoter (PSA-12-LUC), which con-
tains the TATA box and ARE(2170), was approximately 6
times more active in R1881-treated, pARO co-transfected
LNCaP cells than in the absence of hormone (Fig. 3A). Con-
structs PSA-12.1s-LUC and PSA-12.1as-LUC, containing one
ARR copy in sense and antisense orientation, respectively, gave
rise to an increased R1881-induced activity of the promoter
(22–23-fold induction). PSA-12.3-LUC, with three ARR copies,
showed a 185-fold higher promoter activity in the presence of
R1881, clearly indicating cooperativity between the ARR mo-
tifs. Importantly, even three ARR copies did not affect basal
PSA promoter activity in the absence of hormone. This sug-
gested that ARR activity could be directly androgen regulated.
To investigate this further, one or three ARR copies were
inserted in front of a minimal thymidine kinase (TK) promoter
linked to the LUC gene and co-transfected with pAR0 to
LNCaP cells. Basal TK promoter activity was hardly inducible
by androgen (Fig. 3B). The construct containing one ARR (TK-
1-LUC) showed a 4.7-fold higher LUC activity in the presence
of R1881 than in the absence of hormone. TK-3-LUC (with
three ARR copies) showed a 104-fold induction. In the absence
of hormone, the ARR-TK-LUC reporters had the same activity
as the TK-LUC basal construct.
Gel Retardation Analysis of the ARR—To find out whether
the AR could directly interact with the ARR(2400 to 2366), a
series of in vitro protein-DNA interaction experiments was
carried out. First of all, nuclear extract of LNCaP cells grown in
the presence of R1881 was used to study proteins interacting
with the ARR. Gel retardation analysis with this extract re-
vealed the presence of at least three specific complexes (Fig. 4A,
lanes 1–3). Incubation with antibody Sp197 did not result in a
visible supershift (Fig. 4A, lane 2; compare Fig. 2A for
ARE(2170) shifts), nor could one of the complexes be competed
with an excess of unlabeled ARE(2170) (Fig. 4A, lane 4). Iden-
tical complexes were formed with extracts from cells grown in
the absence or presence of hormone, indicating that the expres-
sion or activity of none of the proteins visualized in Fig. 4B is
androgen regulated.
If in vitro synthesized AR was used in AR-ARR gel retarda-
tion assays in the presence of Sp197 a very weak retarded
complex could be detected (Fig. 4C), suggesting the presence of
a low affinity AR binding site in the ARR. In agreement with
this observation, a 100-fold excess of ARR could partially com-
pete the formation of an ARzARE(2170) complex (Fig. 4C, lanes
3–6). A similar excess of unlabeled ARE completely inhibited
the formation of the ARzARE complex. The unrelated C/EBP
oligo had no effect on ARzARE complex formation. The most
sensitive assay, gel retardation with AR(DBD), produced in E.
coli clearly revealed the formation of an AR(DBD)zARR com-
plex (Fig. 4D).
Analysis of the AR-binding Segment in ARR—To find the
precise sequence in ARR which was responsible for AR binding,
FIG. 2. Gel retardation analysis of ARzARE(2170) complexes. A, 20 3 103 cpm of ARE(2170) was incubated with LNCaP nuclear extract,
and complexes were analyzed by polyacrylamide gel electrophoresis as described under “Materials and Methods.” Incubations were in the absence
(lane 1) or presence (lanes 2–4) of antibody Sp197. Incubation of ARE with Sp197, without nuclear extract did not give rise to a complex (data not
shown). Specific, supershifted ARzARE complexes are indicated by an arrow (lanes 2 and 4). Sequences of the oligonucleotides containing the
ARE(2170) and the nonspecific C/EBP competitor (lane 4) are given under “Materials and Methods” (see for the 2170 ARE also the underlined
sequence below the figure). B, 40 3 103 cpm of ARE(2170) was incubated with in vitro synthesized full-length AR, and ARzARE(2170) complexes
were analyzed by polyacrylamide gel electrophoresis as described under “Materials and Methods.” Lanes 1 and 2, ARE with reticulocyte lysate,
containing in vitro synthesized AR. Incubations were in the absence (lane 1) and presence (lane 2) of antibody Sp197. Arrows indicate the position
of the ARzARE complex (lane 1) and supershifted ARzARE complex (lane 2). C, gel retardation analysis of AR(DBD)zARE(2170) complexes. Lane
1, free ARE(2170) probe (50 3 103 cpm). The arrow indicates the position of the AR(DBD)zARE complex. Lane 2, 50 3 103 cpm of ARE(2170) was
incubated with AR(DBD) expressed in E. coli, and purified as described under “Materials and Methods.” Subsequently, the reaction mixture was
analyzed by polyacrylamide gel electrophoresis.
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the ARR was subdivided into three partially overlapping frag-
ments. Gel retardation assay with AR(DBD) and the three ARR
subfragments 1S (GTGGTGCAGGGATCAGGGAG (2400 to
2381)), 2S (CAGGGATCAGGGAGTCTCAC (2394 to 2375)),
and 3S (GAGTCTCACAATCTCCTG (2383 to 2366)) showed
that 2S contained the AR binding sequence, no or extremely
weak binding was detected with 1S and 3S (Fig. 5A).
Next, three copies of 1S, 2S, and 3S were inserted in front of
the minimal PSA promoter construct PSA-12-LUC and co-
transfected with pAR0 to LNCaP cells. The construct contain-
ing three copies of the 1S region (PSA-1S-LUC) gave rise to a
9.6-fold higher activity in the presence of R1881 than in the
absence (Fig. 5B). Construct PSA-2S-LUC, containing three
copies of 2S gave rise to a 128-fold higher activity upon R1881
treatment. The construct with three copies of 3S (PSA-3S-LUC)
produced a 7.1-fold higher activity in the presence of R1881. So,
there is complete concordance between the presence of AR
binding and functional, hormone-dependent enhancer activity
in 2S, and the absence of these activities in 1S and 3S.
Analysis of the AR Binding Site in ARR-2S—Sequence align-
ment showed that in 2S the highest percentage of homology to
the ARE consensus sequence is in the sequence GGATCAgg-
gAGTCTC. This sequence deviates in 2 out of 6 most essential
positions, (positions 2, 3, and 5 in each half-site, underlined)
and overall in 6 out of 12 positions from the ARE consensus
GGTACAnnnTGTTCT. To test whether this sequence could
indeed be responsible for low affinity AR binding, gel retarda-
tion analyses were performed with five ARR-2S mutants (mu-
tations are underlined). Two mutants expected to decrease AR
affinity to the putative AR binding site, ARR-2S-1 (GGAT-
GAgggAGTCTC) and ARR-2S-2 (GGATCAgggACTCTC), and
one presumed silent mutant, ARR-2S-3 (GGATCAgcgAG-
TCTC), were tested for their AR binding capacity (Fig. 6A). Gel
retardation experiments confirmed our hypothesis: AR binding
to ARR-2S-1 and ARR-2S-2 was almost completely abolished;
ARR-2S-3 did not show a marked difference in AR affinity as
compared to ARR-2S. AR(DBD) gel retardation with mutants
with a higher homology to the consensus ARE sequence (ARR-
2S-4 and ARR-2S-5: GGATCAgggAGTTCC and GGAACAgggT-
GTTCC, respectively) substantiated these findings.
Next, mutated 2S elements were tested in LNCaP cells for
enhancer activity. To this end, three of the mutant oligonucleo-
tides, 2S-1, 2S-2 (both abolishing AR-binding), and 2S-3 (spacer
mutation), were cloned in front of the minimal PSA promoter
construct PSA-12-LUC. PSA-2S-1-LUC and PSA-2S-2-LUC
were hardly more active than PSA-12-LUC upon R1881 induc-
tion in AR co-transfected LNCaP cells (Fig. 6B). Construct
PSA-2S-3-LUC showed a 100-fold higher activity in the pres-
ence than in the absence of R1881. These data strongly suggest
the importance of the GGATCAgggAGTCTCmotif in androgen-
regulated activity of the ARR in the PSA promoter.
Effect of Glucocorticoid Receptor Overexpression on PSA Pro-
moter Activity—Because on the one hand the DNA motif for
high affinity AR and GR binding is identical and on the other
hand AR and GR might show specificity on individual promot-
ers, we investigated whether GR was able to mediate PSA
promoter activity. LNCaP cells were co-transfected with the
GR expression plasmid PSTC-GR and selected PSA-LUC con-
structs. Without GR co-transfection, no response of the differ-
ent PSA promoters to dexamethasone was observed (data not
FIG. 3. A, effect of the 2400 to 2366
region (ARR) on basal PSA promoter ac-
tivity in LNCaP cells overexpressing the
AR. The ARR is represented by a hatched
triangle, the ARE by a black box, and the
TATA element by a hatched box. B, effect
of the 2400 to 2366 region of the PSA
promoter (ARR) on TK promoter activity
in LNCaP cells overexpressing AR. The
ARR is represented by a hatched triangle.
The mean of luciferase activity and rela-
tive induction levels are from four inde-
pendent, duplicate experiments. Experi-
mental details are identical to those
described in Fig. 1A. The ARR sequence is
single underlined in Fig. 1B.
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shown). As depicted in Fig. 7A, the pattern of PSA promoter
activity induced by dexamethasone in the presence of GR
turned out to be identical to AR mediated activity (compare
with Fig. 1A): the ARE at position 2170 could function as a
glucocorticoid response element and the ARR(2400 to 2366)
was needed for maximal dexamethasone inducibility.
Co-transfection of LNCaP cells with PSTC-GR and the con-
structs containing one and three copies of the ARR(2400)
linked to the minimal PSA promoter or TK promoter showed a
very strong synergistic, dexamethasone induced activity (Fig.
7B). So, the GR seems to act exactly identical to the AR in
activation of the PSA promoter. In fact, under the conditions
used, the GR is an even more potent stimulator of PSA pro-
moter activity than the AR.
Cell Specificity of ARR Activity—To investigate whether
or not steroid hormone induced activity of ARR(2400) was
LNCaP specific, PSA-12-LUC and TK-LUC constructs (see
Figs. 3 and 7B) and pAR0 or PSTC-GR were co-transfected to
several non-prostate cell lines: COS, HeLa, Hep3B, and T47D.
In the non-prostate cell lines, the minimal PSA promoter con-
struct PSA-12-LUC containing the ARE(2170) is at least 2.5-
fold less induced by R1881 and dexamethasone as compared to
the activity in LNCaP cells. Essentially identical results were
obtained in AR and GR induction of ARR-PSA and ARR-TK
constructs. Both activated receptors were able to induce these
promoters far better in LNCaP cells than in other cell types
(AR/PSA-12.3-LUC: 42–97-fold; GR/PSA-12.3-LUC: 26–48-
fold; AR/TK-3-LUC: 18–54-fold; GR/TK-3-LUC: 27–78-fold).
Our data indicate that LNCaP cells contain one or more factors,
which positively affect PSA minimal promoter activity and
ARR(2400) activity. It is tempting to speculate that this fac-
tor(s) directly or indirectly interacts with a steroid receptor
bound to its response elements.
DISCUSSION
In the present study, analysis of prostate-specificity and
androgen-regulation of the PSA promoter is performed in
LNCaP cells, the only available prostate-derived cell line that
endogenously expresses the PSA gene in an androgen depend-
ent fashion (34). Two regions in the PSA promoter were iden-
tified which are essential for androgen stimulation in LNCaP
cells.
The first region (ARE) encompassed the imperfect palin-
dromic sequence AGAACAgcaAGTGCT at 2170 to 2156 (see
Figs. 1B and 2). Comparison of this sequence with a GGTA-
CAnnnTGTTCT ARE/glucocorticoid response element consen-
sus sequence (4–6) revealed four deviations. However, none of
these was at one of the six positions (positions 2, 3, and 5 in
each half-site), most critical for high affinity AR binding and/or
functional activity (4, 6). The ARE(2170) by itself gave rise to
a weak activation of the PSA promoter (approximately 2-fold
without pAR0 co-transfection). It had to cooperate with the
second androgen response region: ARR (2400 GTGGTGCAGG-
GATCAGGGAGTCTCACAATCTCCTG 2366) for high, andro-
gen induced activity. This ARR contains a low affinity AR
binding site. Results of both gel retardation and transfection
experiments indicate an important role of the sequence GGAT-
CAgggAGTCTC, which is a degenerated palindromic sequence
(6 out of 12 positions are identical to the consensus ARE:
GGTACAnnnTGTTCT). Low AR affinity can probably be ex-
plained by deviation from the consensus sequence at position 3
in the 59-part (T instead of A) and at position 5 (T instead of C)
FIG. 4. Gel retardation analysis of ARzARR complexes. A, 40 3 103 cpm of ARR was incubated with LNCaP nuclear extract, and complexes
were analyzed as described under “Materials and Methods.” Complex formation was in the absence (lane 1) or presence (lanes 2–4) of antibody
Sp197. Incubation of ARR with Sp197, without nuclear extract did not give rise to a retarded band (data not shown). Competition experiments were
in the presence of a 100-fold excess ARR(2400) (lane 3) and ARE(2170) (lane 4). ARR and ARE sequences are presented below the figure. B, 40
3 103 cpm of ARR was incubated with nuclear extract of LNCaP cells grown in steroid depleted medium for 6 days and an additional 24 h in the
presence (lane 2) or absence (lane 1) of 1 nM R1881. C, 20 3 103 cpm of ARR was incubated with in vitro synthesized full-length AR, in the absence
(lane 1) and presence (lane 2) of antibody Sp197, and subsequently analyzed by polyacrylamide gel electrophoresis as described under “Materials
and Methods.” Lanes 3–6, 40 3 103 cpm of ARE incubated with in vitro synthesized AR. Complexes were analyzed by gel retardation assay as
described under “Materials and Methods.” Incubations were in the presence of antibody Sp197. Competition was with 100-fold excess ARE(2170)
(lane 4), ARR (lane 5), C/EBP (lane 6). The arrow indicates the position of supershifted ARzARR and ARzARE complexes. D, gel retardation analysis
of AR(DBD)zARR complexes. Lane 1, free ARR probe. Lane 2, 50 3 103 cpm ARR was incubated with AR(DBD) expressed in E. coli and purified
as described under “Materials and Methods” and subsequently analyzed by polyacrylamide gel electrophoresis. The arrow indicates the position
of the AR(DBD)zARR complex.
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in the 39-part of the palindromic sequence.
Although several androgen-regulated genes have been de-
scribed, only few functional AREs have been studied in detail.
The mechanism of PSA promoter regulation by androgens
seems different from other genes studied in this respect. In the
mouse vas deferens protein gene promoter, two ARE sequences
are present (35). Only the proximal ARE is functionally active,
and no synergism between the two AREs was detected. In the
probasin promoter, also two fragments, which are important
for androgen-regulation of the promoter and which bind AR,
can be found (36, 37). Although both sequences are able to
interact with AR outside the probasin promoter context, both
AR binding sites are individually functionally inactive, even
three copies of the two separated AR binding sites fail to give
rise to androgen-induced reporter gene activity. This is in con-
trast to the AR binding sites in the PSA promoter, ARE(2170)
and ARR-2S, which are clearly independently active, and when
multimerized act synergistically (Ref. 23, and this study).
Three candidate AREs have been found in the C3 gene; only
one of them, Core II, C, is functionally active in transfection
experiments (38–40). Activity of Core II is strongly enhanced
by surrounding sequences including candidate OCT-1 and NF-I
binding sites (41).
Functional synergism between multiple ARE-like sequences
and binding sites for other transcription factors has been found
in the complex enhancer elements of the 20-kDa protein and
Slp genes. In the androgen responsive enhancer in the pro-
moter of the Slp gene, three tandemly repeated hormone re-
sponse element-like sequences are present (42). Additionally,
several non-receptor binding elements contribute to the char-
acteristic androgen response of this complex enhancer (43). The
first intron of the 20-kDa protein gene contains a cluster of
three ARE-like half-sites spanning a 39-base pair fragment
(N39) which shows AR binding and confers weak androgen
responsiveness to a heterologous promoter. Additional se-
quences surrounding this cluster of ARE-like sequences are
needed for full activity of this enhancer (44). These additional
sequences include a region (D2) that shows high AR binding
affinity and androgen induced transcriptional activity, but no
candidate ARE sequences were identified. Taking into consid-
eration the results obtained in our present study, which show
that multiple weak AR binding sites can give rise to strong
androgen inducibility, weak AREs might be postulated to be
present in the D2 region. Like the Slp and C3 promoter, non-
steroid receptor factors, including OCT-1 are supposed to be
involved in establishment of the full AR specific response of the
20-kDa protein promoter.
The complex promoters of the Slp and 20-kDa protein genes
show an AR, but no GR response in transfection assays, al-
though both AR and GR are able to bind and induce activity of
smaller enhancer fragments (42, 44). Both AR and GR are able
to stimulate probasin promoter activity, however, AR is mark-
edly more potent than GR in this respect (36). This in contrast
to results on the PSA promoter presented in this study. Co-
transfection of LNCaP cells with PSA-LUC constructs and a
GR expression plasmid showed that GR can replace AR in high,
steroid hormone-regulated PSA promoter activation. This is
not only related to the ARE(2170), but is also true for the ARR
at 2400. Preliminary evidence indicates that GR is also able to
activate the promoter of the endogenous PSA gene in LNCaP
cells.2 From these findings we conclude that the apparent AR
specificity of the PSA promoter in LNCaP cells is due to the
absence of other members of the steroid receptor family in this
particular cell line. The absence of PSA expression in GR or AR
positive, non-prostate cells must be explained by additional
inhibitory mechanisms in these cells or absence of other essen-
tial regulatory proteins involved in PSA expression.
Transfection experiments further indicated that ARR(2400)
and minimal PSA promoter activity (including ARE(2170)) are
cell dependent. We studied this aspect in more detail for
ARR(2400). Even in the presence of high levels of AR and GR,
ARR(2400) activity in LNCaP cells is much higher than in the
2 K. B. J. M. Cleutjens, unpublished data.
FIG. 5. Analysis of the AR binding segment in ARR. A, gel
retardation analysis of AR(DBD)zARR subfragment complexes. 50 3
103 cpm of ARR-1S (lanes 1 and 2), -2S (lanes 3 and 4), and -3S (lanes
5 and 6) were incubated with AR(DBD) and analyzed by gel retardation
assay as described under “Materials and Methods.” 1S, 2S, and 3S
sequences are shown below the figure. The arrow indicates the position
of the AR(DBD)zARR-2S complex. B, effect of the ARR-1S (2400 to
2381), -2S (2394 to 2375), and -3S (2383 to 2366) on PSA basal
promoter activity in LNCaP cells overexpressing the AR. The ARR
subfragments are represented by triangles, the ARE(2170) by a black
box, and the TATA box by a hatched box. Mean values and S.E. are from
three independent, duplicate experiments. Further experimental de-
tails are identical to those described in the legend to Fig. 1A.
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FIG. 6.Mutation analysis of the ARR-2S segment. A, gel retardation analysis of ARR-2S and ARR-2S mutants with AR(DBD). 50 3 103 cpm
of ARR-2S (lanes 1 and 2), ARR-2S-1 (lanes 3 and 4), -2S-2 (lanes 5 and 6), -2S-3 (lanes 7 and 8), -2S-4 (lanes 9 and 10), and -2S-5 (lanes 11 and
12) were incubated with AR(DBD) and analyzed by gel retardation assay as described under “Materials and Methods.” Sequences of ARR-2S and
ARR-2S mutants are shown below the figure. The arrow indicates the position of the AR(DBD)-probe complex. B, effect of the ARR-2S-1, -2S-2, and
-2S-3 sequences on PSA basal promoter activity in LNCaP cells overexpressing the AR. ARR-2S and mutant ARR-2S oligo’s are represented by
triangles, the ARE(2170) by a black box, and the TATA box by a hatched box. Mean values of luciferase activity and induction levels and their
respective S.E. are from three independent, duplicate experiments. Experimental details are as described in the legend to Fig. 1A. Closed bar,
activity in the presence of R1881 (1 nM); open bar, activity in the absence of hormone.
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non-prostate cell lines tested (Table I). This indicates that in
addition to AR or GR, other factors are involved in steroid
receptor regulated PSA promoter activation. These factors
might be present in a higher concentration in LNCaP cells than
in the non-prostate cell lines tested. Candidates regarding
ARR(2400) could be the proteins detected in gel retardation
experiments with the ARR(2400) and LNCaP nuclear extract
(Fig. 4A). However, these factors are not androgen regulated
(Fig. 4B) and in gel retardation experiments using nuclear
extracts from the non-prostate cell lines COS, T47D, HeLa,
and Hep3B essentially the same protein complexes could be
found (data not shown). The absence of LNCaP specific
ARR(2400)zprotein complexes may be due to a relative weak or
unstable interaction of these factors with the ARR(2400). Al-
TABLE I
Effect of R1881 (A) and dexamethasone (B) on ARR(2400) PSA promoter and ARR(2400) TK promoter activity in
COS, HeLa, Hep3B, T47D, and LNCaP cells co-transfected with (A) the androgen receptor expression
plasmid pARO and (B) glucocorticoid receptor expression plasmid PSTC-GR
Construct
Relative induction (6 hormone)a
LNCaP COS HeLa Hep3B T47D
A PSA-12-LUCb 4.4 6 1.7 1.1 6 0.1 1.1 6 0.4 1.8 6 0.4 1.1 6 0.2
PSA-12.3-LUC 127 6 28 2.0 6 0.3 3.1 6 0.8 3.1 6 0.8 1.3 6 0.2
TK-LUC 1.5 6 0.2 1.1 6 0.1 1.1 6 0.3 1.1 6 0.3 0.8 6 0.1
TK-3-LUC 81 6 22 2.1 6 0.4 2.0 6 0.9 4.4 6 2.0 1.5 6 0.3
B PSA-12-LUC 8.9 6 2.3 1.3 6 0.3 3.5 6 0.8 3.6 6 1.2 1.8 6 0.4
PSA-12.3-LUC 361 6 83 9.7 6 1.0 7.5 6 1.3 14 6 3.0 13 6 4.7
TK-LUC 1.7 6 0.4 0.8 6 0.2 1.7 6 0.7 1.0 6 0.1 1.1 6 0.1
TK-3-LUC 468 6 101 13 6 1.7 6.3 6 1.9 17 6 3.4 8.2 6 2.6
a Induction factor is the mean of three to seven independent, duplicate experiments 6 S.E.
b Constructs are as described under “Materials and Methods.”
FIG. 7. Effect of glucocorticoid re-
ceptor overexpression on PSA pro-
moter activity in LNCaP cells. A,
LNCaP cells were transfected with PSA
promoter constructs in the presence of the
GR expression plasmid PSTC-GR (see
“Materials and Methods” for experimen-
tal details). After transfection, cells were
cultured in the presence or absence of 10
nM dexamethasone. Closed bar, activity in
the presence of dexamethasone; open bar,
activity in the absence of hormone. Induc-
tion value of the various promoter con-
structs is indicated to the right of each
black bar. Absolute luciferase activity and
induction values are the means of at least
four independent experiments performed
in duplicate. S.E. of luciferase activity is
given by the horizontal bar; S.E. of induc-
tion factor is given in parentheses. B, ef-
fect of the 2400 to 2366 region (ARR) on
minimal PSA and TK promoter activity in
LNCaP cells overexpressing the GR. The
ARR is represented by a hatched triangle,
the ARE by a black box, and the TATA box
by a hatched box. Further experimental
details are as described in A.
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ternatively, specific factors affect AR and GR activity by pro-
tein-protein interaction.
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